Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in Panama

Infection and Immunity

Volumn 67, Issue 4, 1999, Pages 2030-2034

  Taylor, David N ^a,e   Sanchez, José L ^b,f   Castro, José M ^g   Lebron, Carlos ^a   Parrado, Carlos M ^g   Johnson, David E ^g   Tacket, Carol O ^c   Losonsky, Genevieve A ^c   Wasserman, Steven S ^c   Levine, Myron M ^c   Cryz, Stanley J ^d  

^a California   (Peru)

^b US Army Medical Research Unit   (United States)

^c University of Maryland School of Medicine Center for Vaccine Development   (United States)

^d Berna Biotech AG   (Switzerland)

^e WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^f U S ARMY CENTER FOR HEALTH PROMOTION AND PREVENTIVE MEDICINE   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA VACCINE; LIVE VACCINE; PLACEBO;

ADULT; ARTICLE; BACTERIAL VIRULENCE; CHOLERA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ESCHERICHIA COLI; FEMALE; HUMAN; IMMUNOGENICITY; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; MILITARY MEDICINE; ORAL DRUG ADMINISTRATION; PANAMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STRAIN DIFFERENCE; VACCINATION; VIBRIO CHOLERAE;

EID: 0033064419     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.4.2030-2034.1999     Document Type: Article

References (23)

1. Besser, R. E., D. R. Feikin, J. E. Eberhart-Phillips, L. Mascola, and P. M. Griffin. 1994. Diagnosis and treatment of cholera in the United States: are we prepared? JAMA 272:1203-1252.
2. Centers for Disease Control and Prevention. 1997. Health information for international travel 1996-97. U.S. Department of Health and Human Services, Atlanta, Ga.
3. Clemens, J. D., D. A. Sack, J. R. Harris, F. van Loon, J. Chakraborty, F. Ahmed, M. R. Rao, M. R. Khan, M. D. Yunus, N. Huda, B. F. Stanton, B. A. Kay, S. Walter, R Eeckels, A. M. Svennerholm, and J. Holmgren. 1990. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet i:270-273.
4. Clemens, J. D., F. van Loon, D. A. Sack, M. R. Rao, F. Ahmed, J. Chakraborty, B. A. Kay, M. R. Khan, M. Yunus, J. R. Harris, A.-M. Svennerholm, and J. Holmgren. 1991. Biotype as determinant of natural immunising effect of cholera. Lancet 337:883-884.
5. Clements, M. L., M. M. Levine, C. R. Young, R. E. Black, Y.-L. Lim, and R. M. Robins-Browne. 1982. Magnitude, kinetics and duration of vibriocidal antibody response in North Americans after ingestion of Vibrio cholerae. J. Infect. Dis. 145:465-473.
6. Gotuzzo, E., B. Butron, C. Seas, M. Penny, R. Ruiz, G. Losonsky, C. F. Lanata, S. S. Wasserman, E. Salazar, J. B. Kaper, S. Cryz, and M. M. Levine. 1993. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect. Immun. 64:3994-3997.
7. Kenner, J. R., T. S. Coster, D. N. Taylor, A. F. Trofa, M. Barrera-Oro, T. Hyman, J. M. Adams, D. T. Beattie, K. P. Killeen, D. R. Spriggs, J. J. Mekalanos, and J. C. Sadoff. 1995. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1. J. J. Infect. Dis. 172:1126-1129.
8. Kotloff, K. L., S. S. Wasserman, S. O'Donnell, G. A. Losonsky, S. J. Cryz, and M. M. Levine. 1992. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial. Infect. Immun. 60:4430-4432.
9. Levine, M. M., J. B. Kaper, D. Herrington, J. Ketley, G. Losonsky, C. O. Tacket, B. Tall, and S. Cryz. 1988. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet ii:467-470.
10. Levine, M. M., C. R. Young, R. E. Black, Y. Takeda, and R. A. Finkelstein. 1985. Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains and to cholera toxin: application in serodiagnosis and seroepidemiology. J. Clin. Microbiol. 21:174-179.
11. Michalski, J., J. E. Galen, A. Fasano, and J. B. Kaper. 1993 CVD 110, an attenuated Vibrio cholerae O1 El Tor live oral vaccine strain. Infect. Immun. 61:4462-4468.
12. Naficy, A., M. R. Rao, C. Paquet, D. Antona, A. Sokin, and J. D. Clemens. 1996. Treatment and vaccination strategies to control cholera in sub-Saharan refugee settings: a cost-effectiveness analysis. JAMA 279:521-525.
13. Sanchez, J. L., and D. N. Taylor. 1997. Cholera. Lancet 349:1825-1830.
14. Simanjuntak, C., P. O'Hanley, N. H. Punjabi, F. Noriega, G. Pazzaglia, P. Dykstra, B. Kay, Suharyono, A. Budiarso, A. R. Rifai, S. S. Wasserman, G. Losonsky, J. Kaper, S. Cryz, and M. M. Levine. 1993. Safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine strain CVD 103-HgR in 24-59-month-old Indonesian children. J. Infect. Dis. 168:1169-1176.
15. Su-Arehawaratana, P., P. Singharaj, D. N. Taylor, C. Hoge, A. Trofa, K. Kuvanont, S. Migasena, P. Pitisuttitham, Y. L. Lim, G. Losonsky, J. B. Kaper, S. S. Wasserman, S. Cryz, P. Echeverria, and M. M. Levine. 1992. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J. Infect. Dis. 165:1042-1048.
16. Suharyono, C. Simanjuntak, N. Witham, N. Punjabi, D. G. Heppner, G. Losonsky, H. Totosudirjo, A. R. Rifai, J. Clemens, Y. L. Lim, D. Burr, S. S. Wasserman, J. Kaper, K. Sorenson, S. Cryz, and M. M. Levine. 1992. Safety and immunogenicity of a single-dose, live oral cholera vaccine CVD 103-HgR in 5-9-year old Indonesian children. Lancet 340:689-694.
17. Tacket, C. O., K. L. Kotloff, G. Losonsky, J. P. Nataro, J. Michalski, J. B. Kaper, R. Edelman, and M. M. Levine. 1997. Volunteer studies investigating the safety and efficacy of live oral El Tor Vibrio cholerae O1 vaccine strain CVD 111. Am. J. Trop. Med. Hyg. 56:533-537.
18. Tacket, C. O., G. Losonsky, J. P. Nataro, S. J. Cryz, R. Edelman, J. B. Kaper, and M. M. Levine. 1992. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J. Infect. Dis. 166:837-841.
19. Taylor, D. N., K. P. Killeen, D. C. Hack, J. R. Kenner, T. S. Coster, D. T. Beattie, J. Ezzell, T. Hyman, A. Trofa, M. H. Sjogren, A. Friedlander, J. J. Mekalanos, and J. C. Sadoff. 1994. Development of a live, oral, attenuated vaccine against El Tor cholera. J. Infect. Dis. 170:1518-1523.
20. Taylor, D. N., J. Rizzo, R. Meza, J. Perez, and D. Watts. 1996. Cholera among Americans living in Peru. Clin. Infect. Dis. 22:1108-1109.
21. Taylor, D. N., C. O. Tacket, G. Losonsky, O. Castro, J. Gutierrez, R. Meza, J. P. Nataro, J. B. Kaper, S. S. Wasserman, R. Edelman, M. M. Levine, and S. J. Cryz. 1997. Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru. Infect. Immun. 65:3852-3856.
22. World Health Organization. 1998. Cholera in 1997. Wkly. Epidemiol. Rec. 73:201-208.
23. World Health Organization. 1993. Guidelines for cholera control. World Health Organization, Geneva, Switzerland.